Patrick R. O'Neil, Executive Vice President, CLO & General Counsel at Ionis Pharmaceuticals Inc (NASDAQ:IONS), sold 1,700 shares of common stock on September 12, 2025. The shares were sold at a weighted average price of $64.5807, resulting in a total transaction value of $109,787. Prices ranged from $64.53 to $64.605.

On the same day, O'Neil also exercised options to acquire 1,700 shares of Ionis Pharmaceuticals at a price of $56.78, for a total value of $96,526.

Following these transactions, O'Neil directly owns 57,130 shares of Ionis Pharmaceuticals.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 2, 2025.

In other recent news, Ionis Pharmaceuticals announced that its experimental drug ION582 has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the treatment of Angelman syndrome. This designation is based on promising results from the Phase 1/2 HALOS study, which indicated clinical improvements in communication, cognition, and motor function for patients. Additionally, Ionis Pharmaceuticals reported positive results from its Phase 3 CORE and CORE2 trials for severe hypertriglyceridemia, showing significant benefits in triglyceride reduction and acute pancreatitis risk mitigation. These developments have led to increased analyst interest, with RBC Capital raising its price target for Ionis to $80, citing the potential of its acute pancreatitis treatment. Meanwhile, H.C. Wainwright increased its price target to $95, highlighting strong triglyceride reductions in pivotal studies. Ionis also celebrated the 10th anniversary of its Surf Away+ event, which supports individuals with rare neurological diseases. These recent developments underscore the company's ongoing efforts in rare disease treatment and drug development.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.